According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
A number of other equities research analysts have also weighed in on the company. Canaccord Genuity upgraded Nuvista Energy to a buy rating in a research note on Tuesday, April 9th. HC Wainwright lowered their price objective on Conatus Pharmaceuticals from $14.00 to $8.00 and set a buy rating for the company in a research note on Monday, March 11th. Finally, William Blair restated an outperform rating on shares of Aileron Therapeutics in a research note on Monday, May 6th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $4.33.
Shares of NASDAQ:ALRN opened at $0.65 on Monday. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.38. Aileron Therapeutics has a one year low of $0.52 and a one year high of $5.39. The company’s 50-day moving average is $0.85.
Aileron Therapeutics (NASDAQ:ALRN) last announced its earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). On average, equities analysts forecast that Aileron Therapeutics will post -1.11 earnings per share for the current year.
An institutional investor recently raised its position in Aileron Therapeutics stock. Jennison Associates LLC raised its holdings in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) by 649.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,040,255 shares of the company’s stock after purchasing an additional 1,768,073 shares during the quarter. Jennison Associates LLC owned 13.72% of Aileron Therapeutics worth $3,828,000 at the end of the most recent quarter. 29.17% of the stock is currently owned by institutional investors and hedge funds.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Recommended Story: How to identify percentage decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.